Transforming the landscape of colorectal cancer treatment with immunotherapy: Evolution and future horizons

Q3 Medicine Cancer treatment and research communications Pub Date : 2024-01-01 DOI:10.1016/j.ctarc.2024.100807

Jan Clerick, Aude Van Oosterwyck, Saskia Carton

{"title":"Transforming the landscape of colorectal cancer treatment with immunotherapy: Evolution and future horizons","authors":"Jan Clerick, Aude Van Oosterwyck, Saskia Carton","doi":"10.1016/j.ctarc.2024.100807","DOIUrl":null,"url":null,"abstract":"<div><p>Colorectal cancer (CRC) continues to be one of the most prevalent and lethal cancers worldwide. Over the past decades, immune checkpoint inhibitors (ICIs) have shown to significantly improve patient outcomes in mismatch repair-deficient metastasized CRC. However, widening the scope of this novel treatment modality has been the object of growing interest. This article will review several landmark trials, while exploring various aspects of this rapidly evolving field, including potential neoadjuvant (or even entirely nonsurgical) and adjuvant indications in localized disease. We will also discuss differences between management of rectal and colon cancer, current and expected challenges (eg. resistance, toxicities, pseudoprogression, biomarkers) and other future opportunities including combinations with other therapeutic agents and the role of ICIs in the treatment of both deficient as well as proficient mismatch repair (dMMR and pMMR respectively) CRC.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000194/pdfft?md5=ce28e34b1a8382f122e7522d2118a6a4&pid=1-s2.0-S2468294224000194-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294224000194","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Colorectal cancer (CRC) continues to be one of the most prevalent and lethal cancers worldwide. Over the past decades, immune checkpoint inhibitors (ICIs) have shown to significantly improve patient outcomes in mismatch repair-deficient metastasized CRC. However, widening the scope of this novel treatment modality has been the object of growing interest. This article will review several landmark trials, while exploring various aspects of this rapidly evolving field, including potential neoadjuvant (or even entirely nonsurgical) and adjuvant indications in localized disease. We will also discuss differences between management of rectal and colon cancer, current and expected challenges (eg. resistance, toxicities, pseudoprogression, biomarkers) and other future opportunities including combinations with other therapeutic agents and the role of ICIs in the treatment of both deficient as well as proficient mismatch repair (dMMR and pMMR respectively) CRC.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

用免疫疗法改变结直肠癌治疗格局：演变与未来展望。

结直肠癌（CRC）仍然是全球发病率和致死率最高的癌症之一。在过去的几十年里，免疫检查点抑制剂（ICIs）已证明能显著改善错配修复缺陷转移性结直肠癌患者的预后。然而，扩大这种新型治疗方式的范围一直是人们日益关注的问题。本文将回顾几项具有里程碑意义的试验，同时探讨这一快速发展领域的各个方面，包括局部疾病的潜在新辅助（甚至完全非手术）和辅助适应症。我们还将讨论直肠癌和结肠癌治疗的不同之处、当前和预期的挑战（如耐药性、毒性、假性进展、生物标志物）以及其他未来的机遇，包括与其他治疗药物的联合用药以及 ICIs 在治疗缺乏和熟练错配修复（分别为 dMMR 和 pMMR）的 CRC 中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer treatment and research communications Medicine-Oncology

CiteScore

4.30

自引率

0.00%

发文量

148

审稿时长

56 days

期刊介绍： Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.